> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Office of Translational Sciences Annual Report
- URL: https://www.fdaweb.com/office-of-translational-sciences-annual-report/
- Published: 2024-05-02T12:00:00.000Z
- Updated: 2026-09-14T14:29:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156903

The CDER Office of Translational Sciences 2023 annual report says it highlights achievements in the areas of drug regulatory review; inspections; science and research; advancing tools, technologies, and innovation; administrative operations; and outreach and communication efforts. Activities discussed in the report include:

- promoting scientific collaboration and innovation in drug regulatory review across CDER;
- assuring the validity of clinical trial design and analysis in regulatory decision-making;
- developing and applying quantitative and statistical approaches to decision-making in the regulatory review process;
- overseeing bioavailability/bioequivalence and nonclinical inspections to help ensure that safe and effective new and generic drugs are available;
- aligning the research at CDER with the Center’s goals;
- facilitating the establishment of technology transfer agreements for collaboration with the broader scientific community; and
- maintaining knowledge management databases for improvements in the regulatory review process.